Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

161. Bazedoxifene (Conbriza)and osteoporosis

Bazedoxifene (Conbriza)and osteoporosis 2011. DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis Content tools Share it For every 5 radiological vertebral fractures avoided there is one case of thromboembolism Bazedoxifene is indicated in postmenopausal osteoporosis in women at increased

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

162. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. Full Text available with Trip Pro

Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. To investigate associations between long term dietary intake of calcium and risk of fracture of any type, hip fractures, and osteoporosis.A longitudinal and prospective cohort study, based on the Swedish Mammography Cohort, including a subcohort, the Swedish Mammography Cohort Clinical.A population based cohort in Sweden established in 1987.61,433 women (born between 1914 and 1948) were followed (...) up for 19 years. 5022 of these women participated in the subcohort.Primary outcome measures were incident fractures of any type and hip fractures, which were identified from registry data. Secondary outcome was osteoporosis diagnosed by dual energy x ray absorptiometry in the subcohort. Diet was assessed by repeated food frequency questionnaires.During follow-up, 14,738 women (24%) experienced a first fracture of any type and among them 3871 (6%) a first hip fracture. Of the 5022 women

2011 BMJ

163. Denosumab - Postmenopausal osteoporosis

Denosumab - Postmenopausal osteoporosis Common Drug Review CEDAC Meeting – January 19, 2011; CEDAC Reconsideration – March 22, 2011 Notice of CEDAC Final Recommendation – March 30, 2011 Page 1 of 6 © 2011 CADTH CEDAC FINAL RECOMMENDATION DENOSUMAB (Prolia – Amgen Canada Inc.) Indication: Postmenopausal Osteoporosis Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that denosumab be listed for women with postmenopausal osteoporosis who would otherwise be eligible (...) evaluation of denosumab compared with raloxifene, but had concerns regarding the comparability of the patient populations in the clinical trials that were used to inform the economic evaluation. Background: Denosumab is indicated by Health Canada for the treatment of postmenopausal women at high risk for osteoporotic (fragility) fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

164. Osteoporosis

Osteoporosis © 1998 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Osteoporosis Screening, Diagnosis, and Treatment Guideline Prevention 2 Screening Recommendations and Tests 2 Diagnosis 4 Treatment 5 Goals 5 Lifestyle Modifications/Non-Pharmacologic Options 5 Pharmacologic Options Osteoporosis 5 Low Bone Density (Osteopenia) 7 Patients on Long-term Corticosteroid Therapy 8 Follow-up/Monitoring 9 Patients With Low Bone Density Who Have Not Sustained a Fracture 9 Patients (...) by the individual patient. 2 Prevention The following are effective strategies for preventing osteoporosis: Consume adequate calcium and vitamin D. Grade A Engage in weight-bearing exercise. Grade B For more information, see the Adult Weight Management Guideline. Avoid tobacco use. Grade B For information on tobacco cessation, see the Tobacco Use Guideline. Screening Recommendations and Tests Table 1. Recommendations for when to order a DEXA Population eligible for screening Test(s) Frequency Women aged 65

2011 Kaiser Permanente Clinical Guidelines

165. The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands Full Text available with Trip Pro

The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from (...) as a first-line treatment for the secondary prevention of fragility fractures in women with postmenopausal osteoporosis. The authors concluded that their analysis suggested that zoledronic acid was a cost-effective first-line option. The study methodology was adequate, but limited reporting on key evidence means that it is unclear if the authors' conclusions are appropriate. Type of economic evaluation Cost-utility analysis Study objective The study assessed the cost-effectiveness of zoledronic acid 5mg

2011 NHS Economic Evaluation Database.

166. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy Full Text available with Trip Pro

Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy Pham AN, Datta SK, Weber TJ, Walter LC, Colon-Emeric CS Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to explore the cost-effectiveness of oral bisphosphonate treatment for osteoporosis in women aged 50 to 90 with varying life expectancy. The authors concluded that treatment of women for osteoporosis with oral bisphosphonates was cost-effective regardless of life expectancy

2011 NHS Economic Evaluation Database.

167. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

168. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis

Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

169. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Full Text available with Trip Pro

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cotte FE, De Pouvourville G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of osteoporosis treatment with oral bisphosphonates focusing on the issue of poor persistence in post-menopausal women. The authors concluded that improving persistence with oral bisphosphonate was likely to improve health benefits and reduce costs compared to current levels of treatment adherence

2011 NHS Economic Evaluation Database.

170. Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and meta-analysis

Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

171. Odanacatib for post-menopausal osteoporosis ? first or second line

Odanacatib for post-menopausal osteoporosis ? first or second line Odanacatib for post-menopausal osteoporosis – first or second line Odanacatib for post-menopausal osteoporosis – first or second line NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Odanacatib for post-menopausal osteoporosis – first or second line. Birmingham (...) : National Horizon Scanning Centre (NHSC). Horizon Scanning Review. 2011 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biphenyl Compounds; Osteoporosis, Postmenopausals Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90

2011 Health Technology Assessment (HTA) Database.

172. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women Full Text available with Trip Pro

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women Nayak S, Roberts MS, Greenspan SL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to assess the cost-effectiveness of various screening strategies for osteoporosis in postmenopausal women. The authors concluded that many strategies for screening were cost-effective, including strategies involving screening initiation at age 55 years. No strategy substantially outperformed another. Overall quality of the study

2011 NHS Economic Evaluation Database.

173. [A study on the evaluation standards of osteoporosis in Korea]

[A study on the evaluation standards of osteoporosis in Korea] [A study on the evaluation standards of osteoporosis in Korea] [A study on the evaluation standards of osteoporosis in Korea] Ahn J, Hyun MK, Kim Y, Suh HS, Park S, Park J, Sung YK, Lee EK Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ahn J, Hyun MK, Kim Y, Suh HS, Park S (...) , Park J, Sung YK, Lee EK. [A study on the evaluation standards of osteoporosis in Korea] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-10-002. 2011 Authors' conclusions The budget impact of the osteoporosis coverage extension plan was suggested to be 147 billion Korean won in the 2009 plan and 133.3 billion Korean won in the 2010 plan (the coverage will be extended to the lowest T-score less than -2.5 and one year coverage (scenario 2)) After adjusting for significant

2011 Health Technology Assessment (HTA) Database.

174. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Full Text available with Trip Pro

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L CRD summary The authors concluded that indirect treatment comparisons (...) indicated teriparatide, zoledronic acid and denosumab had the highest probabilities of being most efficacious for non-vertebral and vertebral fractures. In the absence of direct comparisons, the evidence presented may be the best available. However, the authors' conclusions should be considered tentative given limitations of the evidence and synthesis. Authors' objectives To compare the efficacy of nine osteoporosis medications for reducing fractures in post-menopausal women. Searching Seven databases

2011 DARE.

175. Bisphosphonates for Osteoporosis. Full Text available with Trip Pro

Bisphosphonates for Osteoporosis. 21083387 2010 11 23 2011 02 11 1533-4406 363 21 2010 Nov 18 The New England journal of medicine N. Engl. J. Med. Bisphosphonates for osteoporosis. 2027-35 10.1056/NEJMct1004903 Favus Murray J MJ Department of Medicine, University of Chicago, Chicago, IL 60637, USA. mfavus@medicine.bsd.uchicago.edu eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2011 Feb 10;364(6 (...) ):583; author reply 583-4 21306266 N Engl J Med. 2011 Feb 10;364(6):582-3; author reply 583-4 21306267 Aged Bone Density Conservation Agents chemistry pharmacology therapeutic use Diphosphonates chemistry pharmacology therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy physiopathology Structure-Activity Relationship 2010 11 19 6 0 2010 11 19 6 0 2010 12 14 6 0 ppublish 21083387 10.1056/NEJMct1004903

2010 NEJM

176. Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis. Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial Full Text available with Trip Pro

Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis. Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke. Both doses of lasofoxifene increased (...) the risk of venous thromboembolic events. In this report, we provide comprehensive cardiovascular end-point data, including component events comprising the composite end point of major CHD events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different categories of CHD risk.In this study, 8556 women 59 to 80 years of age with osteoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years. Cardiovascular events, including major CHD events

2010 EvidenceUpdates Controlled trial quality: predicted high

177. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada Full Text available with Trip Pro

Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada 20624868 2010 09 27 2018 11 13 1488-2329 182 12 2010 Sep 07 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. E610-8 10.1503/cmaj.080663 Hanley David A DA Departments of Medicine, University of Calgary, Calgary, AB, Canada. dahanley@ucalgary.ca Cranney Ann (...) A Jones Glenville G Whiting Susan J SJ Leslie William D WD Cole David E C DE Atkinson Stephanie A SA Josse Robert G RG Feldman Sidney S Kline Gregory A GA Rosen Cheryl C Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada eng Journal Article Practice Guideline Research Support, Non-U.S. Gov't Review 2010 07 12 Canada CMAJ 9711805 0820-3946 1406-16-2 Vitamin D A288AR3C9H 25-hydroxyvitamin D AIM IM Adult Bone Density drug effects Dietary Supplements adverse effects Fractures

2010 EvidenceUpdates

178. Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention Full Text available with Trip Pro

Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close (...) Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention Gustavo Duque, Jacqueline J Close, Julien P de Jager, Peter R Ebeling, Charles Inderjeeth, Stephen Lord, Andrew J McLachlan, Ian R Reid, Bruce R Troen and Philip N Sambrook Med J Aust 2010; 193 (3): 173-179. || doi: 10.5694/j.1326

2010 MJA Clinical Guidelines

180. Teriparatide (rDNA origin) injection - severe osteoporosis in women

Teriparatide (rDNA origin) injection - severe osteoporosis in women Common Drug Review CEDAC Meeting – January 20, 2010 Notice of CEDAC Final Recommendation – March 17, 2010 Page 1 of 5 © 2010 CADTH CEDAC FINAL RECOMMENDATION TERIPARATIDE ACP SUBMISSION (Forteo – Eli Lilly Canada Inc.) Indication: Severe Osteoporosis in Women Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that teriparatide not be listed. Reasons for the Recommendation: 1. Teriparatide costs (...) $15,688 per patient per 18 month course of treatment (the maximum length of time for which teriparatide treatment is recommended by Health Canada) based on its current list price, which is between 15 to 40 times the cost of bisphosphonates. Teriparatide has not been demonstrated to be cost-effective in any subgroup of post- menopausal women with severe osteoporosis. 2. There were no randomized controlled trials meeting the CDR systematic review protocol that evaluated teriparatide in women previously

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review